BSE filing, NSE: GLENMARK. Summary written from the filing by ALFA Finder's alert engine.
Glenmark Pharmaceuticals Ltd: key numbers
- Share price
- ₹2,316.80
- Market cap
- ₹65,386 Cr
- Revenue (annual)
- ₹16,983 Cr
- Net profit (annual)
- ₹1,362 Cr
- P/E (TTM)
- 36.4×Sector 46.1×
- Promoter holding
- 46.65%+0.00% QoQ
- FII holding
- 21.51%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Glenmark Pharmaceuticals Ltd
All →Glenmark Pharmaceuticals Board Meeting Date
Glenmark Pharmaceuticals notified BSE of a board meeting on 05 Nov 2026 to consider unaudited Q2 FY27 results. No financial figures are disclosed in this advance intimation.
Glenmark Pharmaceuticals Product Launch
Glenmark Pharmaceuticals launched Adapalene Gel USP, 0.1% (OTC) in new pump packs in the USA, expanding its dermatology portfolio.
Glenmark Pharmaceuticals Business Update
Glenmark Pharmaceuticals received an Establishment Inspection Report from the U.S. FDA for its Goa facility, which has been assigned a Voluntary Action Indicated status.
Glenmark Pharmaceuticals Annual General Meeting
Glenmark Pharmaceuticals held its 48th Annual General Meeting on September 11, 2026. The company submitted the proceedings, Scrutinizer’s Report, and voting results to the exchanges.
Glenmark Pharmaceuticals Product Launch
Glenmark Pharmaceuticals launched RYALTRIS® nasal spray in Brazil to treat moderate to severe allergic rhinitis, expanding its global respiratory product footprint in Latin America.
Glenmark Pharmaceuticals Credit Rating
India Ratings upgraded Glenmark Pharmaceuticals' long-term bank loans to 'IND AA+' and affirmed short-term ratings at 'IND A1+'.
Other other announcement announcements
All →NIIT Learning Systems Other Announcement
NIIT Learning Systems board recommended appointing Price Waterhouse Chartered Accountants LLP as statutory auditor for five years from the 25th AGM. The incumbent S. R. Batliboi firm completes its second term.
- Execution
- Five consecutive years, from the 25th AGM (2027) until the 30th AGM (2032)
Senores Pharmaceuticals Other Announcement
Senores Pharmaceuticals appointed Talati and Talati LLP as Statutory Auditor for a 60-month term, effective 29 October 2026. The appointment was approved at the board meeting held the same day.
- Execution
- 60 months
Magson Retail & Distribution Other Announcement
Magson Retail submitted its Regulation 76 Reconciliation of Share Capital Audit Report for the quarter ended 30 September 2026. The report shows a 9,15,940 share difference between issued and listed capital, pending exchange listing approval.
Ekennis Software Service Other Announcement
Ekennis Software declared Regulation 23 related party transaction rules non-applicable for H1 FY27, as its paid-up capital and net worth are below SME thresholds. A CA certificate confirms the figures.
Shri Gang Industries and Allied Products Other Announcement
Shri Gang Industries filed its quarterly shareholding pattern dated 23 October 2026. The filing notes pledges, a warrant conversion, and a deceased promoter's shares moved to a nominee.
P N Gadgil Jewellers Other Announcement
P N Gadgil Jewellers filed a Monitoring Agency Report on its QIP proceeds for the quarter ended 30 September 2026. The agency reports no deviation from the stated objects of the Rs 7,000 million issue.